



## Press release |

### **IBA MOLECULAR GRANTED FILTRACIS™ MARKETING APPROVAL IN FRANCE**

**Gif-sur-Yvette, France, October 25, 2010** – [IBA Molecular](#), member of [IBA group](#) and global developer of next generation radiopharmaceuticals, announced today that it received approval to market Filtracis™ in France from the AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé) on September 28, 2010. Filtracis is a radiopharmaceutical kit for the diagnosis of kidney and urinary tract malfunctions.

With the Filtracis marketing approval in France, IBA Molecular can now offer customers a complete range of products for diagnosing renal function, including renal imaging kits Pentacis® and Renocis®. Filtracis also displays a dosimetry which represents an advantage in pediatric use.

Filtracis allows IBA Molecular to target a significant part of a market estimated at six million Euros. Through the European Union's Mutual Recognition Procedure (MRP), IBA Molecular plans to extend the Filtracis marketing approval to other countries, with the first approvals expected before the end of 2011.

"We are pleased to officially announce the addition of Filtracis to our product portfolio, which covers the majority of nuclear medicine indications, from general to niche," said François Labarre, vice president, Europe of IBA Molecular. "We continually work to transform promising molecules into new radiopharmaceutical products in order to bring personalized medicine and improved diagnosis and treatment of illness to healthcare. This key milestone will support this mission as we focus on life-threatening renal function."

Filtracis is a radiopharmaceutical kit made of 2mg of N,N'-ethylene -(L,L) -dicysteine to be radiolabeled with Technicium 99 (Tc99m).

# # #

#### **About IBA Molecular and IBA group**

IBA Molecular is global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. With radiopharmaceutical discovery-to-delivery development capabilities that address indications in oncology, cardiology and neurology, in PET, SPECT and therapy, IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and making molecular imaging a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular was awarded Frost & Sullivan's European Radiopharmaceuticals Technology Leadership of the Year prize in 2010. Headquartered in Gif-sur-Yvette, France, IBA Molecular is a member of the Belgium-based IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).



## Press release |

Please visit [www.iba-molecular.com](http://www.iba-molecular.com) and [www.iba-worldwide.com](http://www.iba-worldwide.com) for more information about IBA Molecular and IBA group.

**Media contact:**

Christina Aplington  
Ballou PR for IBA Molecular  
+33 – 01 42 22 93 65  
[christina@balloupr.com](mailto:christina@balloupr.com)